Research Index entry · Trial
A slower start for donanemab cut brain swelling by about a third
- Evidence
- People · trial
- Source
- alzforum.org
- Added
- 2 October 2026
What it is
Donanemab (Kisunla) is a drug given by drip that clears amyloid. In the TRAILBLAZER-ALZ 6 trial, starting it on a slower dose schedule cut ARIA-E, the brain swelling these drugs can cause, by about a third. In people with two copies of APOE4, the gene variant that raises both Alzheimer’s risk and swelling risk, it fell from 57 percent to 24 percent.
Where it stands
- Lab discovery
- Animal studies
- First studies in people
- Large trials
- Approved
An approved drug, now with a gentler way to start it, which eases the main worry families have about these drugs.
Update timeline
What changed
Newest first. Only changes to the subject itself appear here: new information, or something proven wrong.
- WatchingThe Scouts look again every Friday
Only new information or a correction shows up here, not another mention of the same thing.
- Update